Related Experiment Video
Updated: May 1, 2026

Real-Time Void Spot Assay
Published on: February 10, 2023
Contemporary issues with pharmacotherapy for lower urinary tract symptoms
1The Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Two articles evaluated common pharmacotherapies for lower urinary tract symptoms (LUTS) in real-world practice. These studies assessed treatments for storage, voiding, and postmicturition issues affecting men and women.
Area of Science:
- Urology
- Pharmacology
- Clinical Practice
Background:
- Lower urinary tract symptoms (LUTS) are common and affect both men and women.
- LUTS encompass storage, voiding, and postmicturition symptoms, increasing with age.
- Real-life clinical practice data is crucial for understanding pharmacotherapeutic effectiveness.
Purpose of the Study:
- To evaluate the use of two key pharmacotherapeutic classes for LUTS.
- To assess the real-world application of LUTS treatments.
- To provide insights into managing common urinary tract issues.
Main Methods:
- Review of two articles published in November 2012.
- Focus on pharmacotherapeutic agents for LUTS.
- Analysis of clinical practice data.
Main Results:
- The articles evaluated specific pharmacotherapies for LUTS.
- Real-life usage patterns and outcomes were examined.
- Findings relate to storage, voiding, and postmicturition symptom management.
Conclusions:
- The evaluated pharmacotherapies are important for managing LUTS in clinical practice.
- Understanding real-world use informs treatment strategies for LUTS.
- Further evaluation of LUTS pharmacotherapies is warranted.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Drug Therapy
Antianxiety Medications
Urinary Tract Infection IV: Nursing Management
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Drugs for Treatment of Constipation-Predominant IBS
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

